June 2017 Surety Medicine Teleconference:
Heat Stress Prevention and Management in Surety
WEDNESDAY, 21 June 2017 will bring the next Surety Medicine Teleconference, at 1 pm (1300) Eastern Time. The topic for June is "Heat Stress Prevention and Management in Surety.” The presenter will be a physician who serves as medical director for multiple occupational health clinics
at Army installations in the state of Utah.
To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:
usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil
______________________________________________________________
SCHEDULE OF SURETY MEDICINE
TELECONFERENCES FOR FY 2017
| Date Topic |
|
19 JUL 2017 |
Syncopal Conditions: Impacts on PRP Reliability |
|
16 AUG 2017 |
Key Stakeholders in the ASAP -- Developing an Alliance
with the CMA |
|
20 SEP 2017 |
Abuse, Dependence, and Substance Use Disorders: DSM-IV-TR vs. DSM-5 |
EDUCATION OPPORTUNITY:
2017 BIOLOGICAL SELECT AGENTS AND
TOXINS MEDICAL SUPPORT COURSE
The 2017 BSAT Medical Support Course is scheduled for 27-30 June at the Army Medical Department Center and School, San Antonio, TX. This course meets the education requirements of AR50-1 for Biological PRP Competent Medical Authority.
For additional information about this four-day course, including information to attend, send an email request to:
usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil
ALERT: FDA Simplifies Rule for Anthrax PEP
FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS
The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax. The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.
Additional information is available from the FDA at:
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm
ALERT: Autoinjector Shelf Life Extension Program: Current Information
NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM: Many expiration date extensions for autoinjector medications expire in 2017!
Check any auto-injector medication stores you have. Select the link
below for additional information from the FDA.
The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some up to 31 October 2019. Complete FDA information related to the auto-injector shelf life extension program can be found at: http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .
Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors.
_______________________________________________________________